FDA 2017 First Generics Approvals Retain India Imprint
Executive Summary
Indian companies continued to have marked presence in list of first generics approved by US FDA in 2017; clearances include some limited competition drugs and complex products that are vital for Indian firms as they transition their portfolios away from 'plain vanilla' generics.
You may also be interested in...
Copaxone 40mg Generic: FDA Exceeds Mylan's Expectations
FDA approves the product well before Mylan's prediction of 2018.
Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication
By conducting a product development or pre-submission meeting, sponsors can receive a mid-review cycle meeting for a complex product ANDA.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.